Peter Seizer, Medizinische Klinik III, Universitätsklinikum Tübingen, Otfried Müller-Str.10, 72076 Tübingen, Germany, Tel.: +49 7071 29 83160; Fax: +49 7071 29 4473, E-mail:
Thromb Haemost. 2013 Nov;110(5):903-9. doi: 10.1160/TH13-02-0113. Epub 2013 Jul 18.
Matrix metalloproteinases (MMPs) and their inhibitors essentially contribute to a variety of pathophysiologies by modulating cell migration, tissue degradation and inflammation. Platelet-associated MMP activity appears to play a major role in these processes. First, platelets can concentrate leukocyte-derived MMP activity to sites of vascular injury by leukocyte recruitment. Second, platelets stimulate MMP production in e.g. leukocytes, endothelial cells, or tumour cells by direct receptor interaction or/and by paracrine pathways. Third, platelets synthesise and secrete a variety of MMPs including MMP-1, MMP-2, MMP-3, and MMP-14 (MT1-MMP), and potentially MMP-9 as well as the tissue inhibitors of metalloproteinase (TIMPs). This review focuses on platelet-derived and platelet-induced MMPs and their inhibitors.
基质金属蛋白酶（MMPs）及其抑制剂通过调节细胞迁移、组织降解和炎症，对多种病理生理过程具有重要作用。血小板相关的 MMP 活性似乎在这些过程中发挥着主要作用。首先，血小板可以通过白细胞募集，将白细胞来源的 MMP 活性集中到血管损伤部位。其次，血小板通过直接受体相互作用和旁分泌途径，刺激例如白细胞、内皮细胞或肿瘤细胞产生 MMP。第三，血小板合成并分泌多种 MMP，包括 MMP-1、MMP-2、MMP-3 和 MMP-14（MT1-MMP），并可能分泌 MMP-9 以及金属蛋白酶组织抑制剂（TIMPs）。本文主要关注血小板衍生和诱导的 MMP 及其抑制剂。
